Avess Study: 6-Month Data AV Fistula DCB First-in-Human Study Presented at Viva 2020

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

FARAPULSE Pulsed Field Ablation (PFA) System is a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  

Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System

Insulet will present new clinical outcomes data for preschool children with type 1 diabetes using the Omnipod 5 Automated Insulin Delivery System (Omnipod 5).

November 9, 2020

AVESS first-in-human (FIH) study of the company’s Avess™ AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference. Surmodics announced the news today.

AVESS study is a prospective, multi-center, single-arm study to assess the safety and performance of the Avess DCB* when used in the treatment of subjects with obstructive lesions of arteriovenous fistulae (AVF) for hemodialysis.

Six-month data from the study show that target lesion patency at 30 days and 6 months was 100 percent and 90.9 percent, respectively. A single re-intervention was required within 6 months, with no AVFs thrombosed. The study’s primary safety endpoints reported no mortality and no device or procedure-related adverse events at 30 days, and all patients maintained functional AVFs for hemodialysis.

“This first-in-human study demonstrates that the Avess DCB is a safe and promising treatment for AV fistula stenosis, which can lead to vascular access dysfunction, thrombosis and loss,” said Ramon L. Varcoe, MD, MBBS, MS, FRFRACS, PhD, associate professor of vascular surgery at Prince of Wales Hospital (Sydney, New South Wales, Australia) and co-lead investigator for the AVESS FIH clinical study.

“Previous AV fistula studies have demonstrated that DCBs effectively reduce rates of restenosis after percutaneous angioplasty,” added Andrew Holden, MD, MBChB, FRANZCR, EBIR, ONZM, Associate Professor, Director of Interventional Radiology at Auckland City Hospital (Auckland, New Zealand) and co-lead investigator for the AVESS FIH clinical trial. “The Avess DCB is a next-generation DCB that may provide further clinical benefits while minimizing systemic paclitaxel exposure.”

Data presented include 6-month results from 12 patients treated with an Avess DCB between December 2018 and August 2019. The majority of AVFs were radiocephalic (10/12, 83.3 percent) with the stenosis located in the juxta-anastomosis (7/12, 58.3 percent), cannulation zone (2/12, 16.7 percent) and outflow (3/12, 25 percent). All patients completed follow-up at or beyond 6 months.

“Our goal with all of our DCB platforms has been to advance the technology to improve drug transfer and distribution effect on the arterial wall offering the opportunity to use a lower drug dose,” said Gary Maharaj, president and CEO of Surmodics. “We are quite pleased with the AVESS first-in-human study results, which provide vital safety data on the Avess DCB and directional data on its effectiveness. This FIH data strengthens our believe that the Avess DCB could be a safe and promising treatment that improves patient outcomes while reducing the number of interventions needed to maintain patency.”

*The design of the Avess DCB reflects Surmodics’ long-standing industry leadership in the development of surface technology for vascular medical devices. The device includes a proprietary drug-excipient formulation for the balloon coating and is manufactured using a proprietary process to improve coating uniformity. Pre-clinical data have shown a three to five times higher target tissue drug concentration, a more evenly distributed and durable drug effect, and lower incidence of downstream drug concentrations compared to control DCBs.1 The Avess DCB is an investigational device, limited by United States law to investigational use.



Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles